Raptor Pharmaceuticals Corp has revealed that its stockholders have approved the proposals to complete the proposed merger with TorreyPines Therapeutics.
According to the company, the merger is expected to close after the satisfaction or waiver of all closing conditions specified in the agreement, including customary regulatory approvals.
Raptor and TorreyPines entered into this merger agreement on July 27, 2009. Following the completion of the merger, TorreyPines will change its name to Raptor Pharmaceutical Corp. Common stock in the combined company will trade on The NASDAQ Capital Market under the symbol, RPTP.
The merger of Raptor and TorreyPines would create a biopharmaceutical company with a pipeline of mid to late stage clinical development candidates and preclinical drug. These drugs would target platforms designed to improve drug delivery of existing therapeutics for orphan indications and underserved patient populations.
Raptor Pharmaceuticals Corp is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of specialized drug targeting platforms and formulation expertise.
TorreyPines Therapeutics is a biopharmaceutical company providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds.